Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

Critical Care Medicine

Volumn 31, Issue 1 SUPPL., 2003, Pages

  Bernard, Gordon R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated protein C; Clinical trial; Coagulopathy; Drotrecogin alfa (activated); Mortality; Sepsis; Septic shock; Severe sepsis; Treatment; Xigris

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;

ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS;

EID: 0037248228     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301001-00012     Document Type: Review

References (62)

1. Siegel JP: Assessing the use of activated protein c in the treatment of severe sepsis. N Engl J Med, In Press
2. Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
3. Matthay M: Severe sepsis - A new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001; 344:759-762
4. Gilles J: FDA approves first drug for severe sepsis. Washington Post November 22, 2001, p A05
5. Meinert CL: Clinical Trials: Design, Conduct and Analysis. Oxford, UK: Oxford University Press, 1986
6. Zeni F, Freeman B, Natanson C: Antiinflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
7. Assman SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-1069
8. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
9. Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340:1555-1564
10. Goyette RE: Hematology: A Comprehensive Guide to the Diagnosis and Treatment of Blood Disorders. Los Angeles, PMIC, 1997
11. ten Cate H: Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28:9-11
12. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88:2093-2100
13. Hoffmann G, Totzke G, Seibel M, et al: In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med 2001; 29:112-116
14. Schmidt-Supprian M, Murphy C, While B, et al: Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw 2000; 11:407-413
15. Grinnell BW, Hermann RB, Yan SB: Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994; 4:221-225
16. Molino M, Woolkalis MJ, Reavey-Cantwell J, et al: Endothelial cell thrombin receptors and PAR-2. J Biol Chem 1997; 272:11133-11141
17. Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappa B in pulmonary disease. Chest 2000; 117:1482-1487
18. Joyce DE, Gelbert L, Ciaccia A, et al: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199-11203
19. Yan SB, Dhainaut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29:S69-S74
20. Chiron announces results of Phase III study of tifacogin in severe sepsis. Available at: http://www.chiron.com/investor/news/index.htm. Accessed April 15, 2002
21. Warren BL, Eid A, Singer P, et al: KyberSept Trial Study Group. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001 286:1869-1878
22. Esmon C: The protein C pathway. Crit Care Med 2000; 28(Suppl):S44-S48
23. Taylor FB, Wada H, Kinasewitz G: Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: Toward a better definition of DIC. Crit Care Med 2000; 28(Suppl):S12-S19
24. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925
25. Murakami K, Okajima K, Uchiba M, et al: Activated protein c attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-647
26. Murakami K, Okajima K, Uchiba M, et al: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272:L197-L202
27. Taylor FB, Chang ACK, Peer GT: DEGR-factor Xa blocks disseminated intravascular coagulation initiated by E. coli without preventing shock or organ damage. Blood 1991; 78:364-368
28. Harada N, Okajima K, Isobe H: Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting induction of nitric oxide synthase. Abstr. Shock 1999; 12:A167
29. Randolph MM, White GL, Kosanke SD: Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - A comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. Thromb Haemost 1998; 79:1048-1053
30. Yan SB, Helterbrand JD, Hartman DL, et al: Low levels of protein C are associated with poor outcomes in severe sepsis. Chest 2001; 120:915-922
31. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336:912-918
32. Hesselvik JF, Malm J, Dahlback B, et al: Protein C, protein S, C4b-binding protein in severe infection and septic shock. Thomb Hemost 1991; 65:126-129
33. Mesters RM, Helterbrand J, Utterback BG, et al: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000; 28:2209-2216
34. Leclerc F, Hazelzet J, Jude B, et al: Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases. Intensive Care Med 1992; 18:202-205
35. Powars D, Larsen R, Johnson J, et al: Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993; 17:254-261
36. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925
37. O'Leary EC, Schelm JA, Simpson PJ: Activated recombinant human protein C does not attenuate recruitment of neutrophils in rat models of acute inflammation. J Pharmacol Exp Ther 1995; 273:193-198
38. Hancock WW, Tsuchida A, Hau H, et al: The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc 1992; 24:2302-2303
39. Roback MG, Stack AM, Thompson C, et al: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 1998; 9:138-142
40. Aoki Y, Ota M, Katsuura Y, et al: Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung/Drug Res 2000; 50:809-815
41. Esmon CT: Protein C, protein S, and thrombomodulin. In: Hemostasis and Thrombosis. Fourth Edition. Hirsh J, Marder VJ, Colman RW, et al (Eds). Philadelphia, Lippincott Williams & Wilkins, 2001, pp 335-353
42. Snow TR, Deal MT, Dickey DT, et al: Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation 1991; 84:293-299
43. Mizutani A, Okjima K, Uchiba M, et al: Activated protein C reduces the ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95:3781-3787
44. Bernard GR, Wright TJ, Ely EW et al: Safety and dose-relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis. Crit Care Med 2001; 29:2051-2059
45. Ely EW, Bernard GR, Vincent JL: Letter to the Editor. N Engl J Med, In Press
46. FDA briefing document for XIGRIS™ for the treatment of severe sepsis. Eli Lilly and Company. September 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf. Accessed April 12, 2002
47. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663
48. Calandra T, Gerain J, Heumann D, et al: High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991; 91:23-29
49. Angus DC, Vincent JL, Artigas A, et al: The effect of recombinant human activated protein C (RHAPC) on organ dysfunction and functional recovery in severe sepsis. Abstr. Crit Care Med 2000; 28:A48
50. Natanson C, Esposito CJ, Banks SM, et al: The sirens' song of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931
51. Assman SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-1069
52. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C for severe sepsis. N Engl J Med, In Press
53. Bernard GR, Macias WL, Vincent JL: Drotrecogin alfa (activated) cumulative safety update. Chest, In Press
54. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of murine monoclonal IGM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266:1097-1102
55. Angus DC, Birmingham MC, Balk RA, et al: E5 Murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. JAMA 2000; 283:1723-1730
56. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
57. Business Week. Available at: http://www.businessweek.com/bwdaily/dnflash/mar2002/nf2002037_2428.htm). Accessed July 21, 2002
58. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
59. Anonymous: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction (GISSI). Lancet 1986; 1:397-402
60. Anonymous: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
61. Anonymous: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction (GUSTO). N Engl J Med 1993; 329:673-682
62. Anonymous: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259